Rezvoglar™ (insulin glargine-aglr) injection

3 mL (100 units/mL)

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the indication for Rezvoglar™ (insulin glargine-aglr)?

Rezvoglar is indicated to improve glycemic control in patients with diabetes.

US_cFAQ_REZ011_INDICATION
US_cFAQ_REZ011_INDICATION
en-US

Indication for Rezvoglar

Rezvoglar™ (insulin glargine-aglr) 100 units/mL is a long-acting human insulin analog indicated to improve glycemic control in

  • adults and pediatric patients with type 1 diabetes, and
  • adults with type 2 diabetes.1

Rezvoglar is not recommended for the treatment of diabetic ketoacidosis.1

Reference

1Rezvoglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: February 02, 2022


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical